High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab-Reference-Cited by-同舟云学术

High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab

Published:2023-12 Issue: Volume:168 Page:115709
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Colarusso Chiara^ORCID,Falanga Anna,Terlizzi Michela^ORCID,De Rosa Ilaria,Somma Pasquale,Sommella Eduardo Maria,Caponigro Vichy,Panico Luigi,Salviati Emanuela,Campiglia Pietro,Salatiello Giuseppe,Tramontano Teresa^ORCID,Maiolino Piera,Pinto Aldo,Sorrentino Rosalinda^ORCID

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference24 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med,2010

2. Pembrolizumab versus docetaxel for previously treated, PDL1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Pembrolizumab versus chemotherapy for PD-L1-positive non small- cell lung cancer;Reck;N. Engl. J. Med.,2016

4. Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study;Xu;BMC Cancer,2020

5. Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients;Ji;Platelets 2015; 26:138–42,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients;Biomedicines;2024-04-25

2. PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer;Translational Lung Cancer Research;2024-02